Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials-Reference-Cited by-同舟云学术

Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials

Published:2023-10 Issue:10 Volume:17 Page:102877
ISSN:1871-4021
Container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews
language:en
Short-container-title:Diabetes & Metabolic Syndrome: Clinical Research & Reviews

Author:

Dutta Deep^ORCID,Nagendra Lakshmi,Bhat Sowrabha,Mohindra Ritin,Surana Vineet,Misra Anoop

Publisher

Elsevier BV

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference21 articles.

1. Injectable combination therapies for the management of diabetes: an Indian perspective;Dutta;Expet Opin Drug Metabol Toxicol,2020

2. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial;Bajaj;Diabetes Care,2021

3. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100;Lingvay;Diabetes Care,2021

4. Once-weekly insulin for type 2 diabetes without previous insulin treatment;Rosenstock;N Engl J Med,2020

5. Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials;Ribeiro E Silva;Arch Endocrinol Metab,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program);Biomedicines;2024-08-14